| Followers | 8 |
| Posts | 744 |
| Boards Moderated | 0 |
| Alias Born | 07/16/2006 |
Wednesday, December 13, 2006 10:27:02 AM
I had noticed when I was obtaining background on MediVas that it had an alliance with MicroIslet (www.gsm.uci.edu/clubpages/healthcare/documents/MediVasSlides.pdf). I wonder if MediVas is contributing to MicroIslet's encapsulation technology even though MicroIslet clearly states on its webpage that its technology is licensed from Duke University... MicroIslet’s webpage cartoon for the MicroIslet-P capsule includes a Poly-amino acid membrane separating an Alginate coating from an Alginate liquified core. MediVas specializes in membranes derived from amino acids.
I raise this issue because I view MediVas as a potentially serious competitor to SRDX.
MicroIslet, on the other hand, does not appear to me to have the resources to be an important competitor to Novocell. My negative sentiment about MicroIslet’s competitive position comes from SEC Form 424B3 (dated Nov 15, 2006) where they state:
“We anticipate that our existing funds will be sufficient to fund our operating expenses and capital requirements into the beginning of 2007. We expect to incur substantial additional costs, including costs related to ongoing research and development activities, preclinical studies and trials. In the event funding is not obtained we may be required to curtail operations. These factors raise substantial doubt about our ability to continue as a going concern, and our independent registered public accounting firm has included in its report on our 2005 audited financial statements an explanatory paragraph expressing substantial doubt regarding our ability to continue as a going concern. ”
MicroIslet’s anticipated schedule (per SEC Form 424B3, 11/15/2006) is:
2nd half 2007 (@ $10-12M) - Initiate phase I/II Human Allotransplantation Clinical Trials
2nd half 2008 (@ $4-5M) – File IND Application for Xenotransplantation Clinical Trials
2008-2009 – Initiate Phase I/II Xenotransplantation Clinical Trials
2010 – Initiate Phase III Human Clinical Trials
2010-2011 – Complete Human Clinical Trials and Submit Product to FDA
2011 – Manufacture, market and sell product.
Recent SRDX News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/21/2025 05:15:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:16:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:15:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:14:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:13:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:11:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:10:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:08:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:06:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:04:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 11:03:24 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 11/19/2025 09:48:05 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 11/19/2025 09:32:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/19/2025 09:30:15 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 11/19/2025 02:47:33 PM
FEATURED Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
